Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults

Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease

“…In summary, our work and work of several others [ 21, 27–30 ] determined that plasma Aβ 42 /Aβ 40 may serve as a potential biomarker for predicting elevated brain amyloid in cognitively normal adults. Additionally, the combination of APP669-711/Aβ 42 ratio and Aβ 42 /Aβ 40 ratio may also serve as predictive surrogate for brain amyloid pathology as more studies are investigating a multi-biomarker approach for predicting cognitive decline and amyloid PET positivity [ 45 ]. Plasma p-tau181/Aβ 1 - 42 ratio [ 46 ] and t p-tau 217 [ 47 ] has recently emerged as alternative biomarker for predicting cognitive decline and amyloid PET positivity.…”

Improving Cognitive Function with Nutritional Supplements in Aging: A Comprehensive Narrative Review of Clinical Studies Investigating the Effects of Vitamins, Minerals, Antioxidants, and Other Dietary Supplements

“…These mechanisms encompass a spectrum of pathologies, ranging from microvascular issues [21], including blood-brain barrier (BBB) disruption [22][23][24][25], impaired cerebral blood flow regulation [26][27][28][29], impaired glymphatic function [30], and small vessel disease [31,32] to macrovascular pathologies such as atherosclerosis [33] and stroke. Additionally, neuroinflammation [34,35], synapse loss, white matter damage [36,37] and changes in connectivity [38,39], neuronal metabolic dysfunction [40,41] and amyloid pathologies [42,43] play significant roles in the progression of cognitive impairment and dementia. These multifaceted and interrelated pathologies highlight the complexity of brain aging and the challenges in mitigating cognitive decline.…”